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Cell-cell communication in the brain is controlled by multiple mechanisms, including
proteolysis. Membrane-bound proteases generate signaling molecules from membrane-
bound precursor proteins and control the length and function of cell surface membrane
proteins. These proteases belong to different families, including members of the
“a disintegrin and metalloprotease” (ADAM), the beta-site amyloid precursor protein
cleaving enzymes (BACE), membrane-type matrix metalloproteases (MT-MMP) and
rhomboids. Some of these proteases, in particular ADAM10 and BACE1 have been
shown to be essential not only for the correct development of the mammalian brain,
but also for myelination and maintaining neuronal connections in the adult nervous
system. Additionally, these proteases are considered as drug targets for brain diseases,
including Alzheimer’s disease (AD), schizophrenia and cancer. Despite their biomedical
relevance, the molecular functions of these proteases in the brain have not been explored
in much detail, as little was known about their substrates. This has changed with the
recent development of novel proteomic methods which allow to identify substrates of
membrane-bound proteases from cultured cells, primary neurons and other primary
brain cells and even in vivo from minute amounts of mouse cerebrospinal fluid (CSF). This
review summarizes the recent advances and highlights the strengths of the individual
proteomic methods. Finally, using the example of the Alzheimer-related proteases
BACE1, ADAM10 and γ-secretase, as well as ADAM17 and signal peptide peptidase like
3 (SPPL3), we illustrate how substrate identification with novel methods is instrumental
in elucidating broad physiological functions of these proteases in the brain and other
organs.
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PROTEOLYTIC PROCESSING IN ALZHEIMER’S DISEASE
Proteolysis is a biological process playing an essential role in all organisms and tissues, including
the brain. For example, proteolysis regulates numerous cell functions, spanning from degradation
of faulty proteins to post-translational generation of active signaling molecules, neurite outgrowth
and modeling of the extracellular matrix. Therefore, protease activity must be tightly regulated
and, conversely, aberrant proteolysis is associated with several pathological conditions ranging
from inflammation to cancer and neurodegeneration. A prime example is Alzheimer’s disease
(AD), where deregulation of proteolysis leads to neurodegeneration. AD is the most common
type of dementia, a syndrome characterized by loss of memory and cognitive decline. AD causes
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a substantial loss of neurons and synapses in the brain,
leading to an overall loss in brain weight. Additional
neuropathological hallmarks of the disease are the amyloid-β
(Aβ) plaques, consisting of the mostly 42 amino acid long
Aβ peptide (Aβ42), and the intraneuronal accumulation of
neurofibrillary tangles, consisting of hyperphosphorylated
forms of the microtubule-associated protein tau (Huang
and Mucke, 2012). According to the widely accepted
amyloid cascade hypothesis (Selkoe and Hardy, 2016), Aβ
forms neurotoxic oligomers, which initiate an inflammatory
response involving the activation of microglia and astrocytes.
Subsequently tau becomes aberrantly phosphorylated and
aggregates in neurofibrillary tangles, leading to synaptic loss,
neuronal death, and ultimately dementia (Selkoe and Hardy,
2016).
Aβ derives from the transmembrane protein amyloid
precursor protein (APP; Dislich and Lichtenthaler, 2012;
Figure 1A) through sequential cleavage by two proteases, the
β- and γ-secretase (Haass and Selkoe, 2007). The β-secretase
was identified in 1999 by five independent research groups,
and is referred to as β-site APP cleaving enzyme 1 (BACE1;
Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999;
Yan et al., 1999; Lin et al., 2000). BACE1 cleavage releases a
soluble extracellular fragment of APP (sAPPβ) and generates
a carboxy (C)-terminal membrane-tethered fragment known as
C99 (Figure 1). C99 undergoes a subsequent intramembrane
cleavage by γ-secretase, a multi-subunit protease complex
comprising four transmembrane proteins: presenilin, nicastrin,
Pen2 and Aph1 (De Strooper et al., 2010). The γ-secretase
cleavage of C99 generates Aβ and releases intracellularly the APP
intracellular domain (AICD). APP can undergo an alternative
cleavage, mediated by a disintegrin and metalloproteinase 10
(ADAM10; Lammich et al., 1999; Kuhn et al., 2010), also
known as α-secretase, that releases its soluble ectodomain
(sAPPα) and generates a membrane-tethered fragment, C83
(Figure 1B). Importantly, the subsequent cleavage by γ-secretase
releases a truncated form of Aβ, which is non-toxic. Three
other proteases emerged to be involved in the processing
of APP. Asparagine endopeptidase (AEP), known as the δ-
secretase, is a cysteine proteinase that mediates APP processing
in an age-dependent manner and is linked to AD pathogenesis
(Zhang et al., 2015). Furthermore, the membrane-tethered
metalloproteinase (MT5-MMP) cleaves APP at amino acids
504–505, initiating a proteolytic processing that leads to the
generation of APP fragments (Aη-α), which lower neuronal
activity (Ahmad et al., 2006; Willem et al., 2015; Figure 1C).
Loss of MT5-MMP ameliorates pathology and behavioral deficits
in a mouse model of AD (Baranger et al., 2016). A member
of the meprin family of metalloproteases, meprin β, was also
shown to cleave APP, with the cleavage site being identical to
that of the β-secretase or in close proximity to it. This shedding
event is followed by the γ-secretase cleavage and leads to the
generation of Aβ or truncated variants of Aβ (i.e., Aβ2–40;
Bien et al., 2012). Additionally, meprin β can process APP at
the N-terminus, releasing two N-terminal fragments of APP of
11 and 22 kDa, namely APP11 and APP22 (Jefferson et al.,
2011).
REGULATED INTRAMEMBRANE
PROTEOLYSIS
The proteolytic processing of APP is a prime example for a
proteolytic process referred to as regulated intramembrane
proteolysis (RIP; Figure 2). RIP frequently comprises two
proteolytic cleavages, namely shedding and intramembrane
proteolysis. Shedding is mediated by membrane-tethered
proteases, referred to as ‘‘sheddases’’, which cleave their
transmembrane substrates, thereby releasing their soluble
ectodomains into the extracellular milieu (Figure 2). Most
sheddases cleave their substrates at peptide bonds outside of
the membrane, but at a short distance from the lumenal or
extracellular membrane surface. Shedding can be followed
by a second cleavage within the substrates’ transmembrane
domain. This cleavage results in release of the intracellular
domain (ICD) into the cytosol and the extracellular secretion
of the small remaining peptide. As it occurs for APP,
α- and β-secretase function as sheddases, and their activity
can be coupled with the action of γ-secretase to perform
RIPping of the remaining membrane-tethered protein
fragment.
Shedding and intramembrane proteolysis initiate a sequence
of extracellular and intracellular events that control a broad
range of physiological processes in the brain, including cell-cell
communication, cell differentiation and development (Murphy
et al., 2008; Lichtenthaler et al., 2011; Weber and Saftig,
2012). For instance, the tumor necrosis factor-α (TNF), a
proinflammatory cytokine, is generated as a transmembrane
protein that needs to be shed by ADAM17 from the
cell surface in order to trigger immune responses (Black
et al., 1997). Interestingly, the remaining membrane-bound
fragment can be further cleaved by SPPL2a or SPPL2b within
the membrane, releasing the TNF ICD which acts as an
additional signaling molecule (Friedmann et al., 2006). Similarly
to TNF, several growth factors, including EGF-like growth
factors and neuregulins, are inactive when bound to the
membrane and get activated by proteolytic shedding (Blobel,
2005).
Sheddases do not only modulate the availability of ligands,
but also regulate the activity of signaling receptors. Notch is
a clear example of cell surface receptor that requires RIPping
to initiate its signaling pathway and control cell-differentiation
(Hartmann et al., 2002). For other substrates, RIP is a mechanism
to terminate a protein’s function. For example, shedding shuts
down the signaling function of TNF receptors (D’Alessio et al.,
2012; Deng et al., 2015) or the adhesive functions of cell adhesion
proteins (Solanas et al., 2011).
SHEDDASES AND INTRAMEMBRANE
PROTEASES
Members of several different families of proteases have been
shown to function as sheddases, including several ADAMs,
BACE proteases, membrane-type metalloproteinases (MT-
MMPs) and rhomboids (Figure 2; Blobel, 2005; Vassar et al.,
2014; Itoh, 2015). In addition, signal peptide peptidase like 3
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FIGURE 1 | Schematic representation of amyloid precursor protein (APP) processing. (A) A number of proteases can cleave APP at specific sites, including
a disintegrin and metalloproteinase 10 (ADAM10; yellow arrow), beta-site APP cleaving enzyme 1 (BACE1; red arrow), γ-secretase (orange arrows), asparagine
endopeptidase (AEP; blue arrows), membrane-type matrix metalloproteases (MT5-MMP; fuchsia arrow) and meprin β (green arrows). (B) APP can undergo
amyloidogenic processing when cleaved by BACE1. Cleavage of APP by BACE1 results in generation of sAPPβ. Subsequent cleavage of the remaining
transmembrane domain by γ-secretase releases amyloid-β (Aβ). (C) Conversely, cleavage of APP by ADAM10 favors the non-amyloidogenic pathway, releasing
sAPPα. Subsequent γ-secretase cleavage releases a non-toxic truncated form of the Aβ peptide, called p3. (D) In addition, APP can be cleaved by MT5-MMP, which
results in the release of sAPPη. Consecutively, C-terminal fragment (CTF)-η can be cleaved by ADAM10 or BACE1 that release Aη-α and Aη-β, respectively. The
recently identified δ-secretase cleaves APP a few amino acids N-terminally to the BACE1 cleavage site (not shown in the figure).
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FIGURE 2 | “Shedding” and “RIPping”. Schematic representation of ectodomain shedding and regulated intramembrane proteolysis (RIP), including a list of
protease families known to function as sheddases or intramembrane proteases.
(SPPL3) from the SPP family and site-1 protease (S1P) can also
act as sheddases (Lenz et al., 2001; Voss et al., 2012). ADAM
and BACE proteases cleave substrates in their extracellular
domain, at a short distance from the membrane, and need the
sequential cleavage of an intramembrane proteinase in order
to perform RIPping. Conversely, rhomboids and SPPL3 are
intramembrane proteases that cleave their substrates within
or close to the transmembrane domain. As a consequence
of such cleavage, regardless whether it occurs extracellularly
or within the transmembrane domain, the ectodomain of
substrates is released into the extracellular milieu. This is
of note, as the secreted form of transmembrane proteins
can acquire functions different from that of the membrane-
bound counterpart. MT-MMPs can act as sheddases. However,
compared to the related family of ADAMs, MT-MMPs
can cleave their substrates more distantly from the cell
surface and on different sites, thereby releasing truncated
forms of protein ectodomains or lower molecular weight
fragments (Selvais et al., 2011; Fu et al., 2013; Willem et al.,
2015).
FUNCTION OF PROTEASES IS
DETERMINED BY SUBSTRATES
Proteases have been well characterized in pathophysiology of
disease as key players in the development of several pathological
conditions, including neurodegenerative diseases. Thus, protease
inhibition has been widely targeted for drug development.
Unfortunately, in the vast majority of cases, therapies based
on protease inhibition have failed in clinical trials. Indeed,
there are critical limitations to the development of therapies
targeting proteases. First, distinct members of a protease family
share structural features, thus drug-based inhibition of a specific
protease can affect the activity of homologs. For example,
BACE1 inhibitors have been developed to reduce Aβ production
in the brain and are tested for treatment and prevention
of AD. However, they also block the homologous protease
BACE2, which has critical functions in pigmentation (Rochin
et al., 2013; Neumann et al., 2015). In fact, mice treated
with such inhibitors get a gray fur color and patients treated
with these drugs need to go for regular dermatology testing
(Yan, 2016). More importantly, proteases often do not target
a specific substrate, but they can cleave an array of diverse
proteins. As a consequence, their inhibition can deregulate a
number of cellular processes, and inhibition-based therapies
can lead to mechanism-based side effects that often are more
pronounced than amelioration of the pathology itself. For
instance, due to its central contribution to the pathogenesis
of AD, γ-secretase has been extensively targeted for drug
development. A number of γ-secretase inhibitors have been
generated and tested for their ability to reduce Aβ production
in vitro and in vivo. One of them, called Semagacestat, was
terminated in clinical trial Phase III, as it was associated with
worsening of patient cognition and with higher incidence of
skin cancer (De Strooper, 2014). These mechanism-based side
effects were linked to the chronic inhibition of Notch cleavage
by γ-secretase.
A deep understanding of protease functions and their roles
in cell biology is necessary for developing effective therapeutic
strategies. As the biological function of proteases depends on
their substrate spectrum, the identification of the substrate
repertoire is essential to understand the function of a specific
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protease and to predict potential side-effects of their therapeutic
inhibition. In the last years, a number of proteomics-based
methods have been developed in order to identify the substrate
repertoire of specific proteases. In this review, we summarize
the most commonly used and other suitable methods and give
examples of their applications with a focus on sheddases and
intramembrane proteases, in particular on BACE1, ADAM10
and γ-secretase in AD.
METHODS FOR MASS SPECTROMETRY
BASED SUBSTRATE IDENTIFICATION OF
MEMBRANE PROTEASES IN THE BRAIN
Mass spectrometry (MS) based proteomics offers powerful
methods to identify membrane protease substrate candidates
in vitro and in vivo. Especially, non-targeted quantification of
protein cleavage products in the secretome of brain-derived
primary cells or cell lines, as well as cerebrospinal fluid
(CSF) are suitable for protease substrate identification. In
this context, the secretome comprises all proteins released by
cells into body fluids or into the conditioned medium of
cultured cells. For sheddases such as BACE1 and ADAM10,
the ectodomain of their substrates is released into the
extracellular space. Therefore, usually a loss of function
condition, such as protease KO, knockdown (KD), or inhibition,
is quantitatively compared with related control conditions to
identify substrates. At loss of function conditions, substrate
cleavage is fully or partly prevented which leads to a
reduced abundance of the related cleavage products in the
secretome.
Additionally, some substrates accumulate in the cell
membrane when the target protease does not cleave them.
Therefore, membrane protease substrate candidates might also
be identified by quantitative proteomics due to an increased
abundance within the cell membrane. Alternatively, also gain
of function conditions such as overexpression of the target
protease can be used which leads to increased cleavage activity
and subsequently to increased abundance of substrate cleavage
products in the secretome.
Here, we will provide a short overview of the main methods
for MS-based protease substrate identification with a focus
on methods for sheddase substrate identification. In the first
section, methods are described that are used to identify substrates
in the secretome or on the cell surface (Figure 3). In the
second section, methods are described that also allow protease
cleavage site determination (Figure 4). Usually, bottom-up
proteomics is used for this purpose. Briefly, in all protocols,
secreted or membrane proteins are digested with a protease,
usually trypsin, to create proteolytic peptides. In most cases
those peptides are separated by C18 reversed phase liquid
chromatography (LC) prior to MS analysis. The MS raw data
is searched against a protein database to identify proteotypic
peptides. Relative peptide and protein quantification can be
done by different methods. According to the different protocols
for protease substrate identification, label-free and label-based
quantification methods are used. A detailed explanation of
different quantification methods can be found in several review
FIGURE 3 | Workflow of the glyco-capturing and secretome protein
enrichment with click sugars (SPECS) method for protease substrate
identification.
articles (Bantscheff et al., 2007; Schulze and Usadel, 2010;
Bakalarski and Kirkpatrick, 2016).
Methods for Protease Substrate
Identification
Glyco-capture
Most substrates of sheddases are single-pass transmembrane
or GPI-anchored proteins, which are usually glycosylated
within their ectodomain. According to UniProt reference
database of Homo sapiens (date: 2016-06-30), 92% of all
transmembrane type I (1125 out of 1228, term: SL-9905)
and 83% of all transmembrane type II (347 out of 420,
term: SL-9906) proteins are annotated as glycoproteins (term:
KW-0325). Upon membrane protein cleavage, a part of the
ectodomain is secreted (Figure 2). Glyco-capturing (Figure 3)
facilitates specific enrichment of glycoproteins. In the first
step, cis-diol groups of N- and/or O-linked carbohydrates are
oxidized to aldehydes using periodate. At 1 mM periodate
Frontiers in Molecular Neuroscience | www.frontiersin.org 5 October 2016 | Volume 9 | Article 96
Müller et al. Brain Proteomics
FIGURE 4 | Workflow of the N-terminal amine-based isotope labeling of substrates (N-TAILS), combined fractional diagonal chromatography
(COFRADIC) and subtiligase method for protease substrate identification and cleavage site determination. Labeling of amines in N-TAILS and
COFRADIC can also be performed by isobaric tagging such as iTRAQ or TMT for multiplexing.
mainly sialic acid residues are oxidized whereas all cis-diol
groups can be oxidized with higher concentrations such as
20 mM. The aldehydes can be covalently coupled to a
hydrazide resin (Zhang et al., 2003). Alternatively, amino-
oxybiotin can be used to biotinylate the oxidized sugars
for subsequent pull-down with avidin or streptavidin beads
(Zeng et al., 2009). Both, hydrazone and oxime ligations
are catalyzed by aniline (Dirksen and Dawson, 2008). After
glycoprotein pull-down, proteins are digested with trypsin for
MS analysis.
When glycoproteins are covalently coupled to a hydrazide
resin, the digestion is performed directly on the beads. In this
case, the remaining glycosylated peptides can be released using
peptide-N-glycosidase F (PNGaseF) and analyzed as separate
fraction to further reduce the sample complexity (Zhang et al.,
2003; Stützer et al., 2013). For example, this technique was used
to identify substrates of BACE1 and 2 in pancreatic β-cells by
quantification of N-glycopeptides of cell supernatants and lysates
(Stützer et al., 2013). Glycoprotein labeling is even possible
on the cell surface of living cells (Wollscheid et al., 2009;
Zeng et al., 2009). Here, glycoproteins are labeled covalently
with amino-oxybiotin or biocytin-hydrazide for subsequent
enrichment of glycoproteins or glycopeptides using streptavidin
beads.
A drawback of glyco-capturing is that secretome analyses
usually have to be performed under serum-free conditions
because many serum proteins, such as immunoglobulins, are
also glycosylated. Thereby, peptides from secreted proteinsmight
be masked by the presence of high abundant peptides from
serum protein. However, glyco-capturing might also be used to
identify protease substrates in vivo using plasma or CSF samples
(Table 1).
Secretome Protein Enrichment with Click Sugars
(SPECS)
SPECS was developed to overcome the difficulty of secretome
analysis in the presence of serum or other protein containing
culture media additives (Kuhn et al., 2012; Figure 3). For
example, primary neurons have to be cultured using additives
such as B27 which have a high protein concentration, in
particular of albumin. Quantitative proteomics usually covers
a dynamic concentration range of 3–4 orders of magnitude.
Fetal bovine serum (FBS) has a total protein concentration
of 30–45 mg/ml which includes 17–34 mg/ml of albumin
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TABLE 1 | Advantages and disadvantages of different techniques for membrane protease substrate identification.
Advantages Disadvantages
Glycocapture • Large reduction of sample complexity when analyzing
glycopeptides after PNGaseF release.
• Possible with in vivo material
• Serum-free or serum-depleted medium required
SPECS • Compatible with protein and serum supplements in the
medium
• Facilitates secretome and surfaceome analysis.
• Many peptides for quantification
• No direct protease cleavage site identification (only
semitryptic peptides can be used).
• Only applicable for sheddases
• Not suitable for in vivo analyses
AHA labeling • Compatible with protein and serum supplements in the
medium
• Facilitates secretome and surfaceome analysis
• Many peptides for quantification
• No direct protease cleavage site identification (only
semitryptic peptides can be used)
• Only applicable for sheddases
• Titration of AHA concentration necessary to prevent
toxicity
• Not suitable yet for in vivo analyses
Surface Biotinylation • Efficient pull-down of cell surface proteins
• In vivo analyses are possible
• Secretome analysis difficult
• No trypsin cleavage at biotinylated lysines
Murine CSF • In vivo
• Many peptides for quantification
• Low sample amount (5–15 µl)
• Sampling is difficult (blood or cell contamination)
• KO mice or inhibitor treatment of mice is necessary
TAILS • Direct identification of protease cleavage sites
• Also applicable for soluble proteases (e.g., in vitro
incubation of protein lysate with protease of interest)
• Serum-free or serum-depleted medium required
• TAILS is hard to establish (especially C-TAILS)
• Few peptides for quantification
→ Additional whole secretome analysis of labeled peptides
potentially required
COFRADIC • Direct identification of protease cleavage sites
• Also applicable for soluble proteases (e.g., in vitro
incubation of protein lysate with protease of interest)
• Serum-free or serum-depleted medium required
• HPLC is required for extensive sample fractionation
• Histidine containing peptides are lost in the SCX depletion
step
• Few peptides for quantification
→ Additional whole secretome analysis of labeled peptides
potentially required
Subtiligase • Direct identification of protease cleavage sites
• Also applicable for soluble proteases (e.g., in vitro
incubation of protein lysate with protease of interest)
• Serum-free or serum-depleted medium required
• Large sample amount required
• Few peptides for quantification
→ Additional whole secretome analysis of labeled peptides
potentially required
(FBS-BBT, Rocky Mountain Biologicals, Inc., Missoula, MT,
USA). Thus, conditioned cell culture medium with 10%
FBS contains 1.7–3.4 mg/mL whereas the concentration of
secreted proteins is three orders of magnitude lower (in
the µg/mL range). For example, a concentration of 7.0–7.5
µg/mL was reported for the J774 murine macrophage cell line
cultured in 20 mL serum-free medium (Chevallet et al., 2007).
Therefore, high concentrations of protein supplements lead to
a dramatically decreased quantification of cell-derived secreted
proteins.
For SPECS, azido sugars are used for metabolic
labeling of glycoproteins in cell culture. ManNAz
(N-azidoacetylmannosamine-tetraacylated) is taken up by cells,
converted to N-azidoacetyl-sialic acid and mainly incorporated
into N-linked glycosylation but also into O-glycosylation (Sletten
and Bertozzi, 2011). GlcNAz (N-azidoacetylglucosamine-
tetraacylated) and GalNAz (N-azidoacetylgalactosamine-
tetraacylated) are primarily used to label O-glycans. After
metabolic labeling for usually 24–48 h, shed glycoproteins
in cell supernatant and/or surface glycoproteins are
modified by copper-free alkyne-azide click chemistry with
dibenzocyclooctyne (DBCO)-containing biotinylation reagents.
The biotinylated glycoproteins can be efficiently pulled down
with avidin- or streptavidin-coupled beads for further analysis.
The protocol requires SDS-PAGE fractionation of purified
glycoproteins and in-gel digestion because bovine albumin
within the conditioned medium cannot be completely removed.
However albumin abundance is reduced more than 50-fold
and several hundred glycoproteins were identified in the cell
supernatant (Kuhn et al., 2012). Alternatively, on-bead tryptic
digestion of secreted glycoproteins was reported for low-serum
conditions using alkyne beads for covalent coupling (Roper
et al., 2013). Here, the secretome of stromal cell lines was
directly analyzed under serum-free conditions and compared
to glycoprotein enrichment after ManNAz labeling using
serum-free and low serum (1%) conditions. Overall, only 75
and 100 proteins were identified using SPECS at serum-free
and low serum conditions, respectively. Compared to the whole
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secretome digestion (193 proteins), a significant enrichment
for glycoproteins was reported and 46 additional proteins with
lower abundance could be identified.
SPECS has been used to identify substrates of BACE1 (Kuhn
et al., 2012) and ADAM10 (Kuhn et al., 2016) in murine
primary neuronal cell cultures and of SPPL3 in two different
cell lines (Kuhn et al., 2015). SPECS is a technique that is
well-suited for substrate identification of sheddases in any cell
culture system. Quantification is performed on many peptides
in contrast to enrichment of neo N- or C-termini which relies
on quantification by one or two peptides per protein. Hence,
SPECS offers increased reliability of protein quantification. Yet,
as the method does not enrich specifically terminal peptides,
cleavage sites cannot be automatically inferred from the MS data
(Table 1). However, for some substrates semi-tryptic peptides
were identified and allowed determination of the cleavage
site.
Importantly, SPECS identifies secreted, cell-derived proteins,
regardless of whether they are soluble, secreted proteins or
proteolytically derive from membrane proteins. Thus, SPECS
can also be used for the identification of secreted proteins as
biomarkers. When the research goal is to identify sheddase
substrates, the hit list is simply filtered for membrane proteins
and thus yields the list of substrate candidates.
A variant of SPECS has also been used to label membrane
proteins at the surface of ADAM10-deficient neurons. Compared
to wild-type neurons, a number of membrane proteins were
found to be enriched, suggesting that they may be ADAM10
substrates. In fact, several of them also showed reduced
ectodomain release into the conditioned medium and were
validated as ADAM10 substrates (Kuhn et al., 2016). While
changes in the secretome are mostly used to identify shedding
substrates, these results demonstrate that the enrichment of
substrates in the membrane may be an alternative approach.
Azidohomoalanine Labeling
Azidohomoalanine (AHA) labeling (Dieterich et al., 2006) is
an alternative labeling method of newly synthesized proteins
and is similar to the SPECS method. AHA is an azide-
containing analog of methionine which is incorporated into
proteins via the methionyl-tRNA more slowly than methionine
(Kiick et al., 2002). Eichelbaum et al. (2012) established a
proteomic method using AHA labeling for secretome analysis
in the presence of serum supplements. AHA labeled proteins
in the secretome are covalently bound to alkyne resin via
Cu(I) catalyzed cycloaddition reaction between azide groups
and a terminal alkyne. After stringent washing of the beads,
an on-bead digestion is performed. Proteolytic peptides are
fractionated followed by LC-MS/MS analysis. This method was
used in combination with pulsed stable isotope labeling by
amino acids in cell culture (SILAC) to monitor protein synthesis
and secretion during macrophage activation (Eichelbaum and
Krijgsveld, 2014). This method might also be used with
copper-free alkyne-azide click chemistry with DBCO similar
to SPECS. While SPECS enriches for N-glycosylated proteins,
AHA labeling facilitates capturing of all secreted proteins.
However, a drawback is that cellular toxicity has been observed
for AHA labeling, which is not the case for azido-sugar
labeling. The reason appears to be that AHA, which is not
identical to methionine, but is incorporated into the amino
acid backbone of proteins, may slightly alter the conformation
of numerous cellular proteins leading to cellular toxicity.
In contrast, the modified sugars in SPECS are located at
the outside of the protein structure and are less likely to
affect protein conformation. For the AHA method a careful
titration of the AHA concentration can minimize the cellular
toxicity for every cell type. The AHA method has not yet
been used for protease substrate identification, but may be
well suited for determining sheddase substrates. Compared to
the other methods for protease substrate identification, AHA
labeling and SPECS share similar advantages and disadvantages
(Table 1).
Surface Biotinylation
An alternative approach for the enrichment of cell surface
proteins is their biotinylation using N-hydroxysuccinimide
(NHS) chemistry. Proteins are labeled at amino-groups of
lysine residues and protein N-termini with NHS-biotin for
subsequent pull-down. Even though cell surface biotinylation is
frequently used for proteomics, there are no publications for
membrane protease substrate identification available. However,
this technique was already used to validate MS-based substrate
identifications via immunoblotting (Stützer et al., 2013).
Unfortunately, this approach is not suitable for secretome
analysis because all proteins within the conditioned medium
would be labeled, i.e., also serum proteins and not just the cell-
derived proteins (Table 1). Additionally, labeled lysine residues
are no more accessible for tryptic cleavage which results in long
peptides. To overcome this latter issue, peptides can be further
digested with other proteases such as GluC to get more peptides
with a suitable length for LC-MS analysis.
Cerebrospinal Fluid Proteomics
CSF is the only body fluid that is in direct contact with the
brain. Therefore, CSF proteomics is the only method that
facilitates in vivo secretome analysis of the brain. Ideally, KO
mice are the system of choice to study membrane proteases,
as the proteolytically released substrate ectodomains will be
found in the CSF. While milliliters of CSF can be sampled
from humans, only 5–15 µl can be collected from mice (Liu
and Duff, 2008). This makes proteomic analysis of murine CSF
challenging.
Furthermore, sampling of murine CSF is very susceptible to
contaminations by cells or blood. The quantification of more
than 50% of all CSF proteins is affected even by low levels of
blood contamination (Aasebø et al., 2014). Therefore, sampling
of murine CSF is the most critical part of the proteomic workflow
(Table 1).
An immunodepletion kit from Agilent is available for three
most abundant proteins in murine blood which might also work
for murine CSF. However, depletion or even fractionation of
CSF can lead to sample losses, especially for minute sample
amounts. Many CSF proteins bind to albumin and get co-
depleted (Holewinski et al., 2013) or might bind unspecifically
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to the depletion beads or plastic. Additionally, multi-use of
immunoaffinity depletion columns require efficient stripping of
bound proteins to reduce sample carryover and to maintain
the binding capacity (Gundry et al., 2009). Another study
performed a proteomic analysis of murine CSF that was
immunodepleted with IgY-14 resin which is designed to remove
the 14 most abundant human serum proteins (Cunningham
et al., 2013). Yet, 100 µl of pooled CSF was used, but overall only
289 proteins were identified. Consequently, direct in-solution
digestion without depletion is the method of choice for murine
CSF.
Recently, the workflow for murine CSF proteomics
was optimized and allowed identification and label-free
quantification of BACE1 substrates in mouse brains using
individual wild-type and BACE1−/− mice (Dislich et al., 2015).
This shows the suitability of this approach to identify protease
substrates in vivo by proteomics (Table 1). Additionally, it was
shown that quantitative CSF proteome analysis of individual
mice is possible using only 5 µl CSF resulting in 522 relatively
quantified proteins. This was a considerable improvement in
comparison to 128 identified proteins from individual mice
(Smith et al., 2014) and 103 relatively quantified proteins using
pooled murine CSF (Cunningham et al., 2013) in previous
studies.
Methods for Protease Substrate
Identification and Cleavage Site
Determination
Terminal Amine-based Isotope Labeling of
Substrates (TAILS)
Protease cleavage creates neo N- and C-termini. If the
protease of interest is inhibited or knocked-out, the neo
N- and C-terminal peptides are no longer generated. Thus,
identification of neo N- and C-terminal peptides allows both
substrate and cleavage site identification at the same time.
Besides cleavage site determination, the methods for N-termini
identification are also suitable for identification of N-termini
of whole proteins (Vaca Jacome et al., 2015; Berry et al.,
2016). Terminal amine-based isotope labeling of substrates
(TAILS) is a method for specific enrichment of the terminal
peptides. Two different protocols for enrichment of either
protein/peptide N- or C-termini, called N- and C-TAILS are
available (Schilling et al., 2010; Kleifeld et al., 2011). The
first step of N-TAILS is labeling of α- and ε-amines with
methyl groups (dimethyl labeling) or other amino group-reactive
isobaric labeling reagents for proteomics, such as iTRAQ or TMT
reagents (Figure 4). All free protein/peptide N-termini including
the neo N-termini as well as lysine residues are modified. Up
to three different conditions can be relatively quantified by
using stable isotope dimethyl labeling (Boersema et al., 2009)
while up to 10 samples can be relatively quantified with isobaric
labeling.
After labeling of amines, samples from the different
conditions, i.e., protease inhibition and vehicle control, are
mixed. In the next step, the labeled proteins and peptides
are digested by trypsin and/or other endoproteases. This leads
to peptides derived from the former N-term, the C-term, as
well as internal regions called ‘‘internal peptides’’. The peptides
of the former N-termini have no free amino group whereas
all other proteolytic peptides have a new, free amino group.
Dendritic polyglycerol aldehyde polymers are used to remove
all ‘‘internal’’ peptides with free amino groups under mild
reductive conditions using cyano-borohydride. In the last step,
the remaining N-terminal peptides are analyzed by MS.
C-TAILS is the counterpart of N-TAILS which facilitates
the identification of neo C-termini. After dimethyl-labeling,
similar to the N-TAILS protocol, carboxyl groups are protected
with ethanolamine. A tryptic digestion is used to generate
new free N- and C-termini of ‘‘internal’’ peptides. Again,
labeling of α-amines is performed. The ‘‘internal’’ peptides are
removed by coupling the free carboxyl groups to a polyallylamine
polymer. The remaining C-terminal peptides are analyzed
by MS.
TAILS is a powerful technique to identify the exact cleavage
site of a protease. However, the methods require working at
serum-free or low-serum conditions in cell culture for secretome
analysis. For example, secreted proteins of different cell lines,
which were cultured in serum-free medium, were incubated
with recombinant meprin α and β for substrate identification
by N-TAILS (Jefferson et al., 2011, 2013). On the other hand,
in vivo analysis of proteins of cell lysates or membrane fractions
is possible (Sabino et al., 2015; Prudova et al., 2016). Yet,
quantification is based on only one peptide at the N- or
C-terminus of the cleavage site and additionally the N-terminal
peptide of the intact protein. To overcome this issue, routinely
a whole secretome analysis using the labeled peptides after
proteolytic digestion is performed which is used for relative
protein quantification (Prudova et al., 2016). Moreover, for
C-TAILS it has been difficult to achieve complete labeling of
the carboxy-terminal groups, which is a disadvantage for the
analysis of type I membrane protein shedding substrates, where
the N-terminal ectodomain is released into the conditioned
medium and would need to be detected with C-TAILS
(Table 1).
Combined Fractional Diagonal Chromatography
(COFRADIC)
Combined fractional diagonal chromatography (COFRADIC)
is an umbrella term for different multistep chromatographic
methods that include peptide derivatization, fractionation
and isolation of modified peptides. With different types of
modifications, it is possible to separate terminal peptides from
neo N- and C-termini from other peptides (Van Damme et al.,
2010). Usually, two conditions, with and without protease
are differentially labeled in cell culture with SILAC using
isotopic labeled arginine. Proteins are reduced, alkylated at
cysteines and acetylated with NHS-(D3)acetate at α- as well
as ε-amines. After tryptic digestion, N-pyroglutamate residues
are enzymatically removed by pyroglutamyl aminopeptidases
(Abraham and Podell, 1981) because peptides carrying those
residues are usually not charged at pH 3.
Strong cation exchange (SCX) cartridges are used at
pH 3 to remove the majority of peptides with a free
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N-terminus, while most peptides with acetylated N-termini
have a net-charge of zero because the C-terminal arginine is
positively charged but the carboxyl group at the C-term is
mostly deprotonated (Staes et al., 2008; Figure 4). C-terminal
peptides, which contain no C-terminal arginine are also
not positively charged at pH 3 and elute with the flow-
through (Staes et al., 2008). Exceptions are histidine containing
peptides, because histidine residues are positively charged
at a pH of 3. Thus, those peptides are retained by SCX
cartridges.
In the next step, hydrogen peroxide can be used to uniformly
oxidize all methionines. Now, peptides are fractionated by C18
RP chromatography. The free α-amines of C-terminal and
internal peptides in all fractions of both conditions are either
differentially labeled with isotopic variants of NHS-butyrate
(12C4, 13C4) for isolating both (neo) C- and N-terminal peptides.
On the other hand, also isobaric tags might be used to label
primary amines. Alternatively, free α-amines can be labeled
with 2,4,6-trinitrobenzenesulfonic acid (TNBS) which introduces
a very hydrophobic trinitrophenyl label, for isolating (neo)
N-terminal peptides only (Staes et al., 2011).
In the former, the matching fractions of condition 1 and 2 are
combined and a second C18 RP chromatography run is used for
isolating terminal peptides for LC-MS based quantification. For
TNBS labeling, trinitrophenyl containing internal or C-terminal
peptides elute later than in the first C18 RP run which allows
efficient separation of the (neo) N-terminal peptides derived by
protease cleavage.
Relative quantification of N-terminal peptides is done
by SILAC labeling with arginine whereas quantification of
C-terminal peptides is based on the butyrate (or alternative)
labeling. Different studies have been carried out to identify
substrates and cleavage specificities of proteases. For example,
substrate specificities of the granzyme tryptases A and K were
identified (Plasman et al., 2014). In a more general approach,
the secretome of gastric cancer-associated myofibroblasts was
analyzed and identified activation of matrix metalloproteinases
(Holmberg et al., 2013).
COFRADIC facilitates the identification and quantification of
neo N- and C-termini which allows identification of protease
substrates and their cleavage sites. However, extensive HPLC
fractionation as well as LC-MS analysis of many fractions is very
time-consuming. Additionally, histidine containing peptides are
lost during the SCX chromatography step (Table 1).
Subtiligase Method
The subtiligase protocol enables enrichment of free protein
N-termini as well as protease cleavage derived neo N-termini
(Figure 4). A peptide ester which contains a biotin, a
TEV cleavage site and an Abu-tag (α-aminobutyric acid) is
enzymatically coupled to free protein N-termini with subtiligase.
The reaction is specific for α- over ε-amines (Braisted et al.,
1997). Mostly neo N-termini are modified because 68% of the
yeast and 85% of the human proteins are acetylated at the protein
N-term (Van Damme et al., 2011). Labeled proteins/peptides
are pulled down with avidin or streptavidin conjugated beads.
After tryptic digestion and washing, N-terminal peptides
are released using TEV protease. The Abu-tag enables the
discrimination between labeled N-terminal and background
peptides. Quantification can be done label-free or with other
label-based methods (Wiita et al., 2014). Like with TAILS and
COFRADIC, exact cleavage sites of proteases can be analyzed. A
drawback of the method is that typically a high protein amount
of 30–300 mg of cell lysate is used according to Wiita et al. (2014;
Table 1). The subtiligase method was used for different studies,
such as to identify caspase substrate profiles (Agard et al., 2010)
and to analyze cell apoptosis (Crawford et al., 2013).
Summary of Methods
All described methods with the exception of CSF analysis are
suitable for any cell culture experiment including primary cells
as well as cell lines or bacterial cells. However, cells that require
serum or other high protein containing supplements are best
analyzed using SPECS or AHA labeling to enrich selectively for
cell derived proteins. The other methods are better suited for
serum free or low serum conditions.
In vivo samples can be analyzed using all methods except
the metabolic labeling methods SPECS and AHA labeling which
would cause extensive costs for in vivo labeling. In the case
of body fluids, glyco-capturing has the advantage to enrich
for glycosylated proteins which include 89% of type 1 and 2
transmembrane proteins according to UniProt.
TAILS, COFRADIC and the subtiligase method have the
advantage to facilitate protein cleavage site determinations. Thus,
those methods are well suited for cell-free in vitro cleavage
assays such as incubation of cell secretomes, potential substrates,
peptide libraries, or even whole cell lysates with the protease of
interest. Such an approach was reported e.g., for meprin α and β
substrate identification by N-TAILS (Jefferson et al., 2013).
IDENTIFICATION OF MEMBRANE
PROTEASE SUBSTRATES USING
PROTEOMICS
In the following paragraphs we will describe the application
of several of the proteomic methods described above to the
identification of substrates for the Alzheimer-related proteases
BACE1 and BACE2, ADAM10, ADAM17 as well as γ-secretase
and its distant homolog SPPL3.
β-Site Amyloid Precursor Protein Cleaving
Enzyme (BACE) 1 and 2
The beta secretase BACE1 is known to shed the ectodomain
of APP which leads to the release of the sAPPβ fragment.
Subsequently, cleavage of the APP C-terminal fragment (CTF)
by γ-secretase generates amyloid β peptides which can form
plaques in the brain, a pathological hallmark of AD (Selkoe
and Hardy, 2016). Therefore, BACE1, which is highly expressed
in neurons, is a major drug target to inhibit Aβ generation
and thus delaying or preventing the onset of AD. Different
pharmaceutical companies have developed BACE1 inhibitors
(Vassar, 2014). However, several BACE1 inhibitors have failed
in the clinic because of side effects that may not be related
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to BACE1 inhibition (Barão et al., 2016). The inhibition of
BACE1 might also lead to mechanism-based side-effects because
it also cleaves other transmembrane proteins. This is further
emphasized by the finding that BACE1−/− mice show various
phenotypes (Vassar, 2014). Hence, it is essential to identify
BACE substrates and to characterize the biological function of
the full-length proteins as well as the resulting BACE1 cleavage
products.
In recent years, different MS-based proteomic studies
were carried out with the goal to identify BACE substrates
in an unbiased manner. In 2009, Hemming et al. performed
a study with HEK and HeLa cells overexpressing BACE1
and compared the secretome with cells transfected with a
control vector (Hemming et al., 2010). Cells were cultured
and metabolically labeled in serum-free SILAC medium
to enable a MS-based secretome analysis. This study
identified 69 putative BACE1 substrates (65 TM type I, 1
TM type II and 3 GPI anchored proteins) that were enriched
in the secretome of HEK and/or HeLa cells upon BACE1
overexpression. Different hits were further validated by
immunoblotting.
A similar approach was used in a different study (Ivankov
et al., 2013). However, even though well-validated BACE1
substrates such as APP, APLP1 and APLP2 were identified,
overexpression of BACE1 is known to lead to artificial cleavage
of some membrane proteins. One reason is that overexpressed
BACE1 can be active in the endoplasmic reticulum (Huse
et al., 2002), whereas under endogenous conditions it cleaves in
acidic cellular compartments such as trans-Golgi network and
endosomes (Vassar et al., 1999). One example is the protein
LRP1, which was identified as a BACE1 substrate candidate
upon BACE1 overexpression (von Arnim et al., 2005), but
did not show any change in cleavage upon inhibition of
endogenous BACE1, at least not in primary neurons (Kuhn et al.,
2012).
In 2012, two proteomic studies were published which used
primary neurons treated with a BACE inhibitor to identify
proteins with reduced abundance in the secretome. Thus,
these studies were based on endogenous levels of BACE1
and its substrates. The study of Zhou et al. (2012) used
primary neurons cultured in Neurobasal medium without
protein supplements. N-propionylation was used to differentially
label secreted proteins of control and BACE inhibitor treated
samples. Finally, 13 putative BACE substrates could be identified
that showed reduced abundance in the secretome of inhibitor
treated neurons. Additionally, several experiments were carried
out to validate L1 and CHL1 as BACE1 and γ-secretase
substrates.
For the second study of 2012, SPECS was used for primary
neurons treated with a BACE inhibitor or DMSO (Kuhn et al.,
2012). This led to the identification of 34 BACE substrate
candidates. Seven of them were also validated by immunoblots
of BACE inhibitor treated neurons, BACE1−/− neurons and
BACE1−/− brain homogenates.
One of the substrates identified in both proteomic studies
in 2012 is the cell adhesion protein CHL1. Subsequent studies
further validated CHL1 as a BACE1 substrate in vivo and
demonstrated that BACE1-cleavage of CHL1 is required for
correct axon targeting in the olfactory bulb and the hippocampus
of mice (Hitt et al., 2012; Barão et al., 2015).
Another proteomic study used the pancreatic β islet cell
line Min6 to identify BACE1 and BACE2 substrates (Stützer
et al., 2013). This study employed Min6 cells that were
overexpressing BACE1 and/or BACE2, cells with single or
double KDs of BACE1 and BACE2 as well as control cells.
Substrates were identified by glyco-capturing. For validation
of hits from the first screen, the results of seven proteins
were further validated by immunoblotting. The same study also
used primary islets from BACE1−/−, BACE2−/− and BACE
double KO (DKO) mice as well as BACE inhibitor treated islets
for validation. Relative protein quantification of 56 candidates
was performed using targeted proteomics (selected reaction
monitoring). Finally, 40 candidates showed an accumulation
in cell lysates and/or reduced abundance in cell supernatants
(≥1.25-fold) in at least one of the BACE KO or inhibition
conditions. The proteins SEZ6L, SEZ6L2 and TMEM27 were
further validated as BACE2 substrates in murine primary islet
cells (WT vs. BACE1−/−, BACE2−/− and BACE DKO) by
immunoblotting.
Finally, a label-free quantitative proteomic analysis of CSF
from BACE1−/− was performed to identify BACE1 substrates
in vivo (Dislich et al., 2015). In this study, 10 BACE1
substrates or substrate candidates showed to have a significantly
lower abundance in BACE1−/− CSF (APP, APLP1, APLP2,
CHL1, CNTN2, NCAM1, PLXDC2, PAM, PTPRN2, SEZ6L2)
indicating that CSF proteomics is able to identify and validate
BACE1 substrates in vivo. Furthermore, APLP1 and 2 were
validated by immunoblotting and PTPRN2, PLXDC2 as well
as ENPP5 were confirmed by in vitro assays as BACE1
substrates.
Taken together, the long list of BACE1 substrates
demonstrates a central role for BACE1 in basic neurobiology.
Whether the substrates and their functions have an impact on
the suitability of BACE1 as a drug target in AD, remains to be
carefully monitored in future studies.
ADAM10
ADAM10 acts as the constitutively active APP α-secretase
and is a drug target for AD (Jorissen et al., 2010; Kuhn
et al., 2010; Saftig and Lichtenthaler, 2015). ADAM10 is
a ubiquitously expressed metalloprotease of the adamalysin
family that regulates through shedding the function of several
transmembrane proteins, thereby playing a crucial role in cell-
signaling and development. The early embryonic lethality of
ADAM10-deficient mice has been associated with loss of Notch
signaling, that emerged to be a major ADAM10 substrate
(Hartmann et al., 2002). Moreover, mice with a conditional
knock-out of ADAM10 in neurons, show postnatal lethality
at about 3 weeks and display numerous phenotypes in the
brain, including impaired synaptic function and disorganized
laminar architecture of the neocortex. However, the underlying
substrates were largely unknown. A recent study used SPECS
and identified around 90 substrate candidates for ADAM10 in
primary murine neurons (Kuhn et al., 2016). Several of them
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were validated by immunoblots. One of the substrates is the
cell adhesion protein NrCAM for which it was demonstrated
that its loss of cleavage in ADAM10-deficient mice correlates
with deficits in axon targeting in the olfactory bulb in mouse
brains (Kuhn et al., 2016). More of the newly identified ADAM10
substrates are likely to be assigned in the future to the numerous
phenotypes in ADAM10-deficient mice and will enhance our
understanding of the broad neurobiological functions of this
protease.
ADAM17
The metalloprotease ADAM17 is a homolog of ADAM10.
When activated, it can act as an additional α-secretase and
may reduce Aβ levels (Caccamo et al., 2006). ADAM17
is also known as TNF-α converting enzyme (TACE) and
was the first sheddase to be identified, as the enzyme
responsible for releasing the soluble ectodomain of TNF
(Moss et al., 1997). ADAM17 plays a crucial role in cell-
cell communication, being able to release not only TNF, but
also several other transmembrane proteins, including cytokines,
adhesion molecules, receptors and growth factors. ADAM17-
deficient mice display several abnormalities at birth, including
open eyes and skin defects, that phenocopy mice lacking EGF
receptor or a number of its ligands, which are known substrates
of ADAM17 (Blobel, 2005). Most ADAM17 substrates have
been identified through candidate approaches (Qian et al.,
2016). Proteomics has not been extensively used to uncover
ADAM17 substrates. However, a few secretome analyses have
been performed which searched for transmembrane proteins
undergoing shedding in response to specific stimuli, such
as lipopolysaccharide (LPS) and 12-O-tetradecanoylphorbol
13-acetate/Phorbol 12-myristate 13-acetate (TPA/PMA), which
are known to also activate ADAM17. One study identified
a number of transmembrane proteins, such as CSF1R and
Sema4D, that are shed by metalloproteinases in response
to LPS or TPA in macrophage-like cells (Shirakabe et al.,
2014). In order to investigate proteomic changes induced by
LPS in macrophages, one study used a method similar to
SPECS (Eichelbaum and Krijgsveld, 2014), whereas another
group performed secretome analysis from a small number
of cells cultured without serum (Meissner and Mann, 2014).
Together with a list of known substrates of ADAM17,
these studies identified a number of proteins that can also
potentially be cleaved by ADAM17. However, these proteins
were not validated as ADAM17 substrates so far. Another
study specifically investigated changes in the secretome of
ADAM17−/− mouse embryonic fibroblasts (MEFs) by using
SILAC or label-free based approaches (Kawahara et al., 2014).
Label free secretome analysis identified 179 proteins, which
were significantly down-regulated in ADAM17-deficient MEF
cell supernatants. Transmembrane proteins, including TNFR2
and syndecan-4, were strongly reduced in the secretome
of ADAM17−/− MEFs, suggesting that they are ADAM17
substrates. Furthermore, a proteomic study of ADAM17-
deficient epidermis was performed which showed pronounced
changes in a number of proteins involved in barrier formation,
including transglutaminases, involucrin, filaggrin and filaggrin-2
(Tholen et al., 2016).
Functions of ADAM17 in the brain have been little explored
so far and no proteomic study has as yet been done to
address this issue specifically. Yet, the role of ADAM17 in
inflammation suggests that ADAM17 is also involved in various
neuroinflammatory conditions.
γ-Secretase
γ-secretase has been a major drug target in AD in the past.
It is a protease complex that cleaves transmembrane type 1
proteins within or close to their transmembrane domain. While
γ-secretase only directly sheds the ectodomain of a single,
naturally short substrate (Laurent et al., 2015), it typically
requires shedding of its substrates in order to cleave them
within the transmembrane domain. In 2008, a proteomic study
was performed to identify γ-secretase substrates in HeLa cells
(Hemming et al., 2008). Therefore, cells were differentially
labeled with the SILAC method and treated with the γ-secretase
inhibitor DAPT or DMSO as a control. Since γ-secretase
cleavage usually requires previous shedding by other proteases
(Struhl and Adachi, 2000), such as BACE1 or ADAM10,
substrates are commonly identified by an accumulation of
the CTF upon γ-secretase inhibition. Hence, SDS-PAGE of
membrane fractions was applied for proteomic γ-secretase
substrate profiling to separate CTFs from full-length proteins
(Hemming et al., 2008). The gels were cut into 10 slices
and in-gel digestion was performed with trypsin. Relative
quantification between DAPT and DMSO was done separately
for each fraction. CTFs with a DAPT/DMSO intensity ratio
larger than 1.86 were considered as enriched. Overall, CTFs of
13 proteins, among them APP and APLP2 showed enrichment
for DAPT treatment. Very likely, this approach missed to
identify more γ-secretase substrates as CTFs of proteins with
a short cytoplasmic domain are hard to quantify. Additionally,
low molecular weight peptides and proteins offer just few
tryptic peptides and are often lost during washing steps of
the in-gel digestion protocol (Klein et al., 2007; Müller et al.,
2010).
Signal Peptide Peptidase-Like 3 (SPPL3)
The signal peptide peptidase (SPP) family has five members, SPP,
SPPL2A, 2B, 2C and 3. They are distant homologs of γ-secretase
and belong together with γ-secretase to the intramembrane-
cleaving aspartic proteases. The SPP family cleaves type II
transmembrane proteins within or close to their transmembrane
domain (Voss et al., 2013). Similar to most substrates of
γ-secretase, ectodomain shedding by another protease is required
to enable cleavage by SPP, SPPL2A and B (Voss et al., 2013),
whereas it has not been investigated so far if SPPL2C is
proteolytically active and which biological role it has. An
exception to the other family members is SPPL3, which does
not require prior shedding of its substrates by another protease
(Krawitz et al., 2005; Voss et al., 2013). Therefore, type II
transmembrane proteins can be directly shed by SPPL3, which
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is mostly localized in the Golgi apparatus (Krawitz et al., 2005;
Voss et al., 2013).
A global secretome analysis of HEK cells overexpressing
SPPL3 as well as MEF SPPL3−/− cells were used for unbiased
substrate identification (Kuhn et al., 2015). For this purpose,
the SPECS method was applied to enrich and quantify secreted
glycoproteins. The majority of identified SPPL3 substrates are
involved in modifying N- or O-glycosylation. Hence, SPPL3 has
a fundamental role in regulating different protein glycosylation
pathways. Whether and how this role impacts the brain, needs to
be studied in the future.
CONCLUSION AND OUTLOOK
The first substrates of sheddases and intramembrane proteases
were largely identified by candidate approaches, partially driven
by the phenotypes of the corresponding protease knock-outmice.
One example is the loss-of-Notch-function phenotype which
allowed to identify Notch as a substrate for ADAM10 and
γ-secretase (De Strooper et al., 1999; Struhl and Greenwald, 1999;
Hartmann et al., 2002). Another example is the hypomyelination
of BACE1-deficient mice which led to the identification of
neuregulin-1 as a BACE1 substrate (Hu et al., 2006; Willem et al.,
2006).
In the last 10 years the focus has shifted to the use of
proteomics as an unbiased method for the systematic substrate
identification of sheddases— on which we focus in this review,
but also of other proteases, including metalloproteases in
inflammation and caspases in apoptosis. Generally, the field
of proteomics dealing with proteases, protease inhibitors and
protein degradation is referred to as degradomics (López-Otin
and Overall, 2002). Given the advance in mass spectrometric
instrumentation and the development of powerful degradomic
methods as described here, we are likely to see many more
systematic substrate identification studies being published over
the next years. This will include many of the over 40 sheddases
and intramembrane proteases, where substrates and functions
are little understood to date. The degradomics methods are
likely to be further improved to allow analysis of lower sample
amounts, and analyses will be increasingly done with in vivo
material, such as a tissue samples and body fluids.
Several of the sheddases and intramembrane proteases—such
as BACE1, ADAM10, ADAM17 and γ-secretase—are major
drug targets for neurodegeneration or inflammatory diseases.
Other proteases of these families will likely turn out to be drug
targets for additional diseases. Thus, degradomic studies of these
exciting protease families will not only allow us to understand
their basic functions in the brain and other tissues, but will also
enable us to better evaluate their therapeutic potential and to
predict possible side effects of drugs modulating the protease
activity. Additionally, the cleaved ectodomains of the protease
substrates in body fluids, such as CSF, hold the potential to be
used as companion diagnostics for monitoring whether and how
patients respond to protease inhibitors. Thus, the new proteomic
methods have paved the way for even faster discovery in basic
and applied neuroscience and other research fields.
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